EUVIMEDEUVIMED entdecken
Crossref

Clinical development landscape of THR-β agonists in MASLD/MASH: an analysis of clinical trials registered on ClinicalTrials.gov

Raghad Ahmed Y. Al Ameer, Khaled Saad A. Alshehri, Rahma Bin Mosa, Rasil Essa M. Alqahtani, Hazim Nasser Alahmadi, Yasmin Abdulraheem Abdulaziz, Retaj Majed Almabadi, Yusra Hasan AlAbbasi, Taif Mohammed Alharbi, Norah Naffaa Alamri, Areej Mohammedali Munshi

Annals of Middle Eastern Medicine · 17.10.2026 · 2 (5) · 755-767

DOI: 10.24911/amem.15-3114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Middle Eastern Medicine, online erschienen am 17.10.2026. Verfasst von Raghad Ahmed Y. Al Ameer und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction-associated steatohepatitis (MASH), the progressive inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD), is associated with substantial risks of fibrosis progression, cirrhosis, and liver-related morbidity and mortality. The increasing burden of MASLD/MASH has accelerated the development of targeted pharmacological therapies, including thyroid hormone receptor beta (THR-β) agonists. However, the overall clinical development landscape of this therapeutic class has not been comprehensively characterized. This study aimed to characterize the registered clinical trial landscape of THR-β agonists for MASLD/MASH and identify major development trends and evidence gaps.

Methods

A descriptive analysis of clinical trials registered in ClinicalTrials.gov was conducted. Thirty-two records were initially identified and manually screened for eligibility. Eighteen interventional trials involving disease populations within the MASLD/MASH spectrum were included after exclusion of healthy-volunteer clinical pharmacology studies, non-liver indications, observational studies, and unrelated records. Included trials were characterized according to study status, start date period, mapped clinical phase, drug family, therapeutic strategy, clinical focus, sponsorship, geographic distribution, and registry results posting. Categorical variables were summarized using frequencies and percentages, and Fisher’s exact test was used to assess the association between study status and registry results posting. The small sample limited the robustness and generalizability of the findings.

Results

Among the 18 included trials, resmetirom/MGL-3196 was the most frequently investigated THR-β agonist, accounting for 9 studies (50.0%), followed by ASC41/ASC43F with 4 studies (22.2%). Ten trials (55.6%) were phase 2, phase 2a, or phase 2b studies. Most trials were industry-sponsored (17/18, 94.4%), and 15 studies (83.3%) evaluated single-agent THR-β strategies. Eight trials (44.4%) were completed, while 5 (27.8%) were recruiting and 4 (22.2%) were active but not recruiting. Only 2 trials (11.1%) had posted results on ClinicalTrials.gov. The association between study status and registry results posting was not statistically significant (Fisher’s exact test, p = 0.531).

Conclusion

The clinical development landscape of THR-β agonists for MASLD/MASH is active and includes several agents, with resmetirom/MGL-3196 representing the largest development program. However, registry results posting was infrequent; dissemination through publications and other sources was not systematically assessed. More complete registry results posting, broader geographic and academic participation, continued evaluation of combination strategies, and longer-term assessment of efficacy and safety may strengthen the evidence base for this emerging therapeutic class.

Zitieren

APA

Ameer, R. A. Y. A., Alshehri, K. S. A., Mosa, R. B., Alqahtani, R. E. M., Alahmadi, H. N., Abdulaziz, Y. A., Almabadi, R. M., AlAbbasi, Y. H., Alharbi, T. M., Alamri, N. N., & Munshi, A. M. (2026). Clinical development landscape of THR-β agonists in MASLD/MASH: an analysis of clinical trials registered on ClinicalTrials.gov. Annals of Middle Eastern Medicine, 2(5), 755-767. https://doi.org/10.24911/amem.15-3114

Vancouver

Ameer RAYA, Alshehri KSA, Mosa RB, Alqahtani REM, Alahmadi HN, Abdulaziz YA, et al. Clinical development landscape of THR-β agonists in MASLD/MASH: an analysis of clinical trials registered on ClinicalTrials.gov. Annals of Middle Eastern Medicine. 2026;2(5):755-767. doi:10.24911/amem.15-3114

BibTeX
@article{Ameer2026,
  author = {Ameer, Raghad Ahmed Y. Al and Alshehri, Khaled Saad A. and Mosa, Rahma Bin and Alqahtani, Rasil Essa M. and Alahmadi, Hazim Nasser and Abdulaziz, Yasmin Abdulraheem and Almabadi, Retaj Majed and AlAbbasi, Yusra Hasan and Alharbi, Taif Mohammed and Alamri, Norah Naffaa and Munshi, Areej Mohammedali},
  title = {Clinical development landscape of THR-β agonists in MASLD/MASH: an analysis of clinical trials registered on ClinicalTrials.gov},
  journal = {Annals of Middle Eastern Medicine},
  year = {2026},
  volume = {2},
  number = {5},
  pages = {755--767},
  doi = {10.24911/amem.15-3114}
}
Kostenlos starten →